BC is clinically and molecularly classified into [7] different subtypes and stages with different biological, molecular, and clinical outcomes According to the eighth edition of the Tumor, Node, and Metastasis (TNM) system of the American Joint Committee on Cancer (AJCC) of 2018, this disease is classified according to the anatomical information of the tumor, as well as the expression of estrogen receptors (ER), progesterone (PR), and human epidermal growth receptor-2 (HER2) [7,8]. This evidence concerns the gene ESR1 and neoplasm.